Overall, these findings clearly demonstrate that midostaurin, alone or in combination with decitabine, effectively disrupts cell-cycle progression and induces apoptosis in KRAS-driven lung adenocarcinoma organoids, highlighting their therapeutic potential. Here, KRAS is linked to lung adenocarcinoma.